{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:13:11Z","timestamp":1793531591733,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["75N93019C00044"],"award-info":[{"award-number":["75N93019C00044"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["5R21AI137932-02"],"award-info":[{"award-number":["5R21AI137932-02"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["75N93019C00044"],"award-info":[{"award-number":["75N93019C00044"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["272201800047C"],"award-info":[{"award-number":["272201800047C"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["HHSN272200900036C"],"award-info":[{"award-number":["HHSN272200900036C"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","award":["HHSN272201800047C"],"award-info":[{"award-number":["HHSN272201800047C"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during infancy and childhood, but in some cases the full benefit of vaccination is not realized in-part. New adjuvants are cardinal to further optimize current immunization approaches for early life. However, only a few classes of adjuvants are presently incorporated in vaccines approved for human use. Recent advances in the discovery and delivery of Toll-like receptor (TLR) agonist adjuvants have provided a new toolbox for vaccinologists. Prominent among these candidate adjuvants are synthetic small molecule TLR7\/8 agonists. The development of an effective infant\n                    <jats:italic>Bordetella pertussis<\/jats:italic>\n                    vaccine is urgently required because of the resurgence of pertussis in many countries, contemporaneous to the switch from whole cell to acellular vaccines. In this context, TLR7\/8 adjuvant based vaccine formulation strategies may be a promising tool to enhance and accelerate early life immunity by acellular\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    vaccines. In the present study, we optimized (a) the formulation delivery system, (b) structure, and (c) immunologic activity of novel small molecule imidazoquinoline TLR7\/8 adjuvants towards human infant leukocytes, including dendritic cells. Upon immunization of neonatal mice, this TLR7\/8 adjuvant overcame neonatal hyporesponsiveness to acellular pertussis vaccination by driving a T helper (Th)1\/Th17 biased T cell- and IgG2c-skewed humoral response to a licensed acellular vaccine (DTaP). This potent immunization strategy may represent a new paradigm for effective immunization against pertussis and other pathogens in early life.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-20346-w","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T06:03:09Z","timestamp":1666072989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Development of a TLR7\/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-6156","authenticated-orcid":false,"given":"David J.","family":"Dowling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-2125","authenticated-orcid":false,"given":"Soumik","family":"Barman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Chaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer E.","family":"Brightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandolina","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sch\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-3945","authenticated-orcid":false,"given":"Karthik","family":"Siram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Nanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne G.","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-1945","authenticated-orcid":false,"given":"Ofer","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-0272","authenticated-orcid":false,"given":"Jay T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"20346_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix044","author":"JD Cherry","year":"2017","unstructured":"Cherry, J. D. Treatment of Pertussis-2017. J. Pediatric Infect. Dis. Soc. https:\/\/doi.org\/10.1093\/jpids\/pix044 (2017).","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"20346_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/cmr.18.2.326-382.2005","volume":"18","author":"S Mattoo","year":"2005","unstructured":"Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326\u2013382. https:\/\/doi.org\/10.1128\/cmr.18.2.326-382.2005 (2005).","journal-title":"Clin. Microbiol. Rev."},{"key":"20346_CR3","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/01.inf.0000160708.43944.99","volume":"24","author":"T Tan","year":"2005","unstructured":"Tan, T., Trindade, E. & Skowronski, D. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 24, S10-18 (2005).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"20346_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029454","author":"N Burdin","year":"2017","unstructured":"Burdin, N., Handy, L. K. & Plotkin, S. A. What is wrong with pertussis vaccine immunity? the problem of waning effectiveness of pertussis vaccines. Cold Spring Harbor Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a029454 (2017).","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"20346_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00034-17","author":"XX Gu","year":"2017","unstructured":"Gu, X. X. et al. Waning immunity and microbial vaccines-workshop of the national institute of allergy and infectious diseases. Clin. Vaccine Immunol. https:\/\/doi.org\/10.1128\/cvi.00034-17 (2017).","journal-title":"Clin. Vaccine Immunol."},{"key":"20346_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1086\/422035","volume":"190","author":"T Le","year":"2004","unstructured":"Le, T. et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT Study. J. Infect. Dis. 190, 535\u2013544 (2004).","journal-title":"J. Infect. Dis."},{"key":"20346_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1086\/381439","volume":"38","author":"U Heininger","year":"2004","unstructured":"Heininger, U., Cherry, J. D. & Stehr, K. Serologic response and antibody-titer decay in adults with pertussis. Clin. Infect. Dis. 38, 591\u2013594. https:\/\/doi.org\/10.1086\/381439 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"20346_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4049\/immunohorizons.1700057","volume":"2","author":"GG Fouda","year":"2018","unstructured":"Fouda, G. G., Martinez, D. R., Swamy, G. K. & Permar, S. R. The Impact of IgG transplacental transfer on early life immunity. Immunohorizons 2, 14\u201325. https:\/\/doi.org\/10.4049\/immunohorizons.1700057 (2018).","journal-title":"Immunohorizons"},{"key":"20346_CR9","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3201\/eid2109.150023","volume":"21","author":"TH Skoff","year":"2015","unstructured":"Skoff, T. H., Baumbach, J. & Cieslak, P. R. Tracking pertussis and evaluating control measures through enhanced pertussis surveillance, emerging infections program, USA. Emerg. Infect. Dis. 21, 1568\u20131573. https:\/\/doi.org\/10.3201\/eid2109.150023 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"20346_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1586\/14760584.2014.944902","volume":"13","author":"JT Poolman","year":"2014","unstructured":"Poolman, J. T. Shortcomings of pertussis vaccines: Why we need a third generation vaccine. Expert Rev. Vaccines 13, 1159\u20131162. https:\/\/doi.org\/10.1586\/14760584.2014.944902 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"20346_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000000893","author":"DJ Dowling","year":"2015","unstructured":"Dowling, D. J. & Levy, O. Pediatric vaccine adjuvants: Components of the modern vaccinologist\u2019s toolbox. The Pediatric Infect. Dis. J. https:\/\/doi.org\/10.1097\/inf.0000000000000893 (2015).","journal-title":"The Pediatric Infect. Dis. J."},{"key":"20346_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.it.2014.04.007","volume":"35","author":"DJ Dowling","year":"2014","unstructured":"Dowling, D. J. & Levy, O. Ontogeny of early life immunity. Trends Immunol. 35, 299\u2013310. https:\/\/doi.org\/10.1016\/j.it.2014.04.007 (2014).","journal-title":"Trends Immunol."},{"key":"20346_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","volume":"9.","author":"AJ Pollard","year":"2009","unstructured":"Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol 9., 213\u2013220 (2009).","journal-title":"Nat. Rev. Immunol"},{"key":"20346_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.vaccine.2018.11.028","volume":"37","author":"AM Queenan","year":"2019","unstructured":"Queenan, A. M. et al. Increasing FIM2\/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. Vaccine 37, 80\u201389. https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.028 (2019).","journal-title":"Vaccine"},{"key":"20346_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1586\/14760584.2014.936391","volume":"13","author":"AC Allen","year":"2014","unstructured":"Allen, A. C. & Mills, K. H. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev. Vaccines 13, 1253\u20131264. https:\/\/doi.org\/10.1586\/14760584.2014.936391 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"20346_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/INF.0000000000000893","volume":"34","author":"DJ Dowling","year":"2015","unstructured":"Dowling, D. J. & Levy, O. Pediatric vaccine adjuvants: Components of the modern vaccinologist\u2019s toolbox. Pediatr. Infect. Dis. J. 34, 1395\u20131398. https:\/\/doi.org\/10.1097\/INF.0000000000000893 (2015).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"20346_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","volume":"32","author":"E Nanishi","year":"2020","unstructured":"Nanishi, E., Dowling, D. J. & Levy, O. Toward precision adjuvants: Optimizing science and safety. Curr. Opin. Pediatr. 32, 125\u2013138. https:\/\/doi.org\/10.1097\/MOP.0000000000000868 (2020).","journal-title":"Curr. Opin. Pediatr."},{"key":"20346_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590373","author":"D Soni","year":"2020","unstructured":"Soni, D. et al. Towards precision vaccines: Lessons from the second international precision vaccines conference. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.590373 (2020).","journal-title":"Front. Immunol."},{"key":"20346_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cyto.2016.04.001","volume":"83","author":"SD van Haren","year":"2016","unstructured":"van Haren, S. D. et al. In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine 83, 99\u2013109. https:\/\/doi.org\/10.1016\/j.cyto.2016.04.001 (2016).","journal-title":"Cytokine"},{"key":"20346_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"key":"20346_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jaci.2012.02.042","volume":"130","author":"VJ Philbin","year":"2012","unstructured":"Philbin, V. J. et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J. Allergy Clin. Immunol. 130, 195-204 e199. https:\/\/doi.org\/10.1016\/j.jaci.2012.02.042 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"20346_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41590-018-0068-4","volume":"19","author":"M Ugolini","year":"2018","unstructured":"Ugolini, M. et al. Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nat. Immunol. 19, 386\u2013396. https:\/\/doi.org\/10.1038\/s41590-018-0068-4 (2018).","journal-title":"Nat. Immunol."},{"key":"20346_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1365-2567.2012.03587.x","volume":"136","author":"EP Browne","year":"2012","unstructured":"Browne, E. P. Regulation of B-cell responses by Toll-like receptors. Immunology 136, 370\u2013379. https:\/\/doi.org\/10.1111\/j.1365-2567.2012.03587.x (2012).","journal-title":"Immunology"},{"key":"20346_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.4049\/jimmunol.177.3.1956","volume":"177","author":"O Levy","year":"2006","unstructured":"Levy, O. et al. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J. Immunol. 177, 1956\u20131966. https:\/\/doi.org\/10.4049\/jimmunol.177.3.1956 (2006).","journal-title":"J. Immunol."},{"key":"20346_CR25","doi-asserted-by":"publisher","first-page":"e558164","DOI":"10.1371\/journal.pone.0058164","volume":"8","author":"DJ Dowling","year":"2013","unstructured":"Dowling, D. J. et al. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS ONE 8, e558164. https:\/\/doi.org\/10.1371\/journal.pone.0058164 (2013).","journal-title":"PLoS ONE"},{"key":"20346_CR26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaci.2016.12.985","volume":"140","author":"DJ Dowling","year":"2017","unstructured":"Dowling, D. J. et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J. Allergy Clin. Immunol. 140, 1339\u20131350. https:\/\/doi.org\/10.1016\/j.jaci.2016.12.985 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"20346_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12845","author":"BC Holbrook","year":"2017","unstructured":"Holbrook, B. C. et al. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. Immunology https:\/\/doi.org\/10.1111\/imm.12845 (2017).","journal-title":"Immunology"},{"key":"20346_CR28","doi-asserted-by":"publisher","first-page":"e91020","DOI":"10.1172\/jci.insight.91020","volume":"2","author":"DJ Dowling","year":"2017","unstructured":"Dowling, D. J. et al. TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. Science 2, e91020. https:\/\/doi.org\/10.1172\/jci.insight.91020 (2017).","journal-title":"Science"},{"key":"20346_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1753425916651985","author":"MA Pettengill","year":"2016","unstructured":"Pettengill, M. A. et al. Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naive B cells. Innate Immun. https:\/\/doi.org\/10.1177\/1753425916651985 (2016).","journal-title":"Innate Immun."},{"key":"20346_CR30","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1016\/j.vaccine.2017.08.009","volume":"35","author":"A Misiak","year":"2017","unstructured":"Misiak, A. et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine 35, 5256\u20135263. https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.009 (2017).","journal-title":"Vaccine"},{"key":"20346_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-020-01112-y","author":"D Soni","year":"2020","unstructured":"Soni, D., Bobbala, S., Li, S., Scott, E. A. & Dowling, D. J. The sixth revolution in pediatric vaccinology: Immunoengineering and delivery systems. Pediatr. Res. https:\/\/doi.org\/10.1038\/s41390-020-01112-y (2020).","journal-title":"Pediatr. Res."},{"key":"20346_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.smim.2013.05.007","volume":"25","author":"LA Brito","year":"2013","unstructured":"Brito, L. A., Malyala, P. & O\u2019Hagan, D. T. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin. Immunol. 25, 130\u2013145 (2013).","journal-title":"Semin. Immunol."},{"key":"20346_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","volume":"2","author":"DJ Dowling","year":"2018","unstructured":"Dowling, D. J. Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants. Immunohorizons 2, 185\u2013197. https:\/\/doi.org\/10.4049\/immunohorizons.1700063 (2018).","journal-title":"Immunohorizons"},{"key":"20346_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 12, 809\u2013819. https:\/\/doi.org\/10.1586\/14760584.2013.811208 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"20346_CR35","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1128\/AAC.47.12.3846-3852.2003","volume":"47","author":"DN Sauder","year":"2003","unstructured":"Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I. & Meng, T. C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47, 3846\u20133852 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20346_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","volume":"159","author":"RM Szeimies","year":"2008","unstructured":"Szeimies, R. M. et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br. J. Dermatol. 159, 205\u2013210. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08615.x (2008).","journal-title":"Br. J. Dermatol."},{"key":"20346_CR37","doi-asserted-by":"publisher","first-page":"e591020","DOI":"10.1172\/jci.insight.91020","volume":"2","author":"DJ Dowling","year":"2017","unstructured":"Dowling, D. J. et al. TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight 2, e591020. https:\/\/doi.org\/10.1172\/jci.insight.91020 (2017).","journal-title":"JCI Insight"},{"key":"20346_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb1025","author":"SP Kasturi","year":"2020","unstructured":"Kasturi, S. P. et al. 3M\u2013052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abb1025 (2020).","journal-title":"Sci. Immunol."},{"key":"20346_CR39","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","volume":"34","author":"AJ Smith","year":"2016","unstructured":"Smith, A. J. et al. Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants. Vaccine 34, 4304\u20134312. https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.080 (2016).","journal-title":"Vaccine"},{"key":"20346_CR40","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1021\/jm049211v","volume":"48","author":"JF Gerster","year":"2005","unstructured":"Gerster, J. F. et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 48, 3481\u20133491. https:\/\/doi.org\/10.1021\/jm049211v (2005).","journal-title":"J. Med. Chem."},{"key":"20346_CR41","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1021\/acsomega.9b02138","volume":"4","author":"JT Evans","year":"2019","unstructured":"Evans, J. T. et al. Synthetic toll-like receptors 7 and 8 agonists: Structure-activity relationship in the oxoadenine series. ACS Omega 4, 15665\u201315677. https:\/\/doi.org\/10.1021\/acsomega.9b02138 (2019).","journal-title":"ACS Omega"},{"key":"20346_CR42","doi-asserted-by":"publisher","first-page":"126984","DOI":"10.1016\/j.bmcl.2020.126984","volume":"30","author":"HG Bazin","year":"2020","unstructured":"Bazin, H. G. et al. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity. Bioorg. Med. Chem. Lett. 30, 126984. https:\/\/doi.org\/10.1016\/j.bmcl.2020.126984 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20346_CR43","unstructured":"Levy, O., Dowling. D., Bazin, H.G., Burkhart, D., Evans, J., Smith, A.J. Methods and compositions relating to adjuvants. U.S. patent 20200108139 (2020)."},{"key":"20346_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fimmu.2014.00457","volume":"5","author":"MA Pettengill","year":"2014","unstructured":"Pettengill, M. A., van Haren, S. D. & Levy, O. Soluble mediators regulating immunity in early life. Front. Immunol. 5, 457. https:\/\/doi.org\/10.3389\/fimmu.2014.00457 (2014).","journal-title":"Front. Immunol."},{"key":"20346_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.biologicals.2013.08.006","volume":"41","author":"B Mastelic","year":"2013","unstructured":"Mastelic, B. et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biol. J. Int. Assoc. Biol. Standard. 41, 458\u2013468. https:\/\/doi.org\/10.1016\/j.biologicals.2013.08.006 (2013).","journal-title":"Biol. J. Int. Assoc. Biol. Standard."},{"key":"20346_CR46","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/dkr588","volume":"67","author":"NJ Horscroft","year":"2012","unstructured":"Horscroft, N. J., Pryde, D. C. & Bright, H. Antiviral applications of Toll-like receptor agonists. J. Antimicrobial Chemother. 67, 789\u2013801. https:\/\/doi.org\/10.1093\/jac\/dkr588 (2012).","journal-title":"J. Antimicrobial Chemother."},{"key":"20346_CR47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0361-9230(01)00539-1","volume":"55","author":"NL Strominger","year":"2001","unstructured":"Strominger, N. L., Brady, R., Gullikson, G. & Carpenter, D. O. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res. Bull. 55, 445\u2013451. https:\/\/doi.org\/10.1016\/S0361-9230(01)00539-1 (2001).","journal-title":"Brain Res. Bull."},{"key":"20346_CR48","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1073\/pnas.0631696100","volume":"100","author":"J Lee","year":"2003","unstructured":"Lee, J. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 100, 6646\u20136651. https:\/\/doi.org\/10.1073\/pnas.0631696100 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20346_CR49","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1021\/bc900054q","volume":"20","author":"M Chan","year":"2009","unstructured":"Chan, M. et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjugate Chem. 20, 1194\u20131200. https:\/\/doi.org\/10.1021\/bc900054q (2009).","journal-title":"Bioconjugate Chem."},{"key":"20346_CR50","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.tetlet.2016.03.091","volume":"57","author":"HG Bazin","year":"2016","unstructured":"Bazin, H. G., Bess, L. S., Livesay, M. T., Mwakwari, S. C. & Johnson, D. A. Phospholipidation of TLR7\/8-active imidazoquinolines using a tandem phosphoramidite method. Tetrahedr. Lett. 57, 2063\u20132066. https:\/\/doi.org\/10.1016\/j.tetlet.2016.03.091 (2016).","journal-title":"Tetrahedr. Lett."},{"key":"20346_CR51","unstructured":"Bazin, H. G., Johnson, D.A. Pegylated Imidazoquinolines as TLR7 and TLR8 Agonists. U.S. patent 10,882,876 (2017)."},{"key":"20346_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","volume":"3","author":"H HogenEsch","year":"2018","unstructured":"HogenEsch, H., O\u2019Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want. NPJ Vaccines 3, 51. https:\/\/doi.org\/10.1038\/s41541-018-0089-x (2018).","journal-title":"NPJ Vaccines"},{"key":"20346_CR53","volume-title":"Strategies to Modify the Drug Release from Pharmaceutical Systems","author":"ML Bruschi","year":"2015","unstructured":"Bruschi, M. L. Strategies to Modify the Drug Release from Pharmaceutical Systems 1st edn. (Elsevier, 2015).","edition":"1"},{"key":"20346_CR54","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3389\/fimmu.2017.01772","volume":"8","author":"F Borriello","year":"2017","unstructured":"Borriello, F. et al. Identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization. Front. Immunol. 8, 1772. https:\/\/doi.org\/10.3389\/fimmu.2017.01772 (2017).","journal-title":"Front. Immunol."},{"key":"20346_CR55","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1021\/acs.molpharmaceut.8b00579","volume":"15","author":"MA Collier","year":"2018","unstructured":"Collier, M. A. et al. Acetalated dextran microparticles for codelivery of STING and TLR7\/8 agonists. Mol. Pharm. 15, 4933\u20134946. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00579 (2018).","journal-title":"Mol. Pharm."},{"key":"20346_CR56","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1586\/erv.12.118","volume":"11","author":"R Libster","year":"2012","unstructured":"Libster, R. & Edwards, K. M. Re-emergence of pertussis: What are the solutions? Expert Rev. Vaccines 11, 1331\u20131346. https:\/\/doi.org\/10.1586\/erv.12.118 (2012).","journal-title":"Expert Rev. Vaccines"},{"key":"20346_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14760584.2018.1445530","volume":"17","author":"F Martinon-Torres","year":"2018","unstructured":"Martinon-Torres, F., Heininger, U., Thomson, A. & von Wirsing, K. C. H. Controlling pertussis: How can we do it? A focus on immunization. Expert Rev. Vaccines 17, 289\u2013297. https:\/\/doi.org\/10.1080\/14760584.2018.1445530 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"20346_CR58","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(12)60560-1","volume":"379","author":"L Liu","year":"2012","unstructured":"Liu, L. et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 379, 2151\u20132161 (2012).","journal-title":"Lancet"},{"key":"20346_CR59","doi-asserted-by":"publisher","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","volume":"6","author":"TY Wu","year":"2014","unstructured":"Wu, T. Y. et al. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6, 263ra160. https:\/\/doi.org\/10.1126\/scitranslmed.3009980 (2014).","journal-title":"Sci. Transl. Med."},{"key":"20346_CR60","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fimmu.2020.00406","volume":"11","author":"SM Miller","year":"2020","unstructured":"Miller, S. M. et al. Novel lipidated imidazoquinoline TLR7\/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice. Front. Immunol. 11, 406. https:\/\/doi.org\/10.3389\/fimmu.2020.00406 (2020).","journal-title":"Front. Immunol."},{"key":"20346_CR61","doi-asserted-by":"publisher","first-page":"1232910","DOI":"10.1126\/science.1232910","volume":"340","author":"WC Koff","year":"2013","unstructured":"Koff, W. C. et al. Accelerating next-generation vaccine development for global disease prevention. Science (New York N.Y.) 340, 1232910. https:\/\/doi.org\/10.1126\/science.1232910 (2013).","journal-title":"Science (New York N.Y.)"},{"key":"20346_CR62","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/emmm.201403876","volume":"6","author":"I Delany","year":"2014","unstructured":"Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Mol. Med. 6, 708\u2013720. https:\/\/doi.org\/10.1002\/emmm.201403876 (2014).","journal-title":"EMBO Mol. Med."},{"key":"20346_CR63","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1021\/acs.jmedchem.6b00489","volume":"59","author":"A Cortez","year":"2016","unstructured":"Cortez, A. et al. Incorporation of phosphonate into benzonaphthyridine toll-like receptor 7 agonists for adsorption to aluminum hydroxide. J. Med. Chem. 59, 5868\u20135878. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00489 (2016).","journal-title":"J. Med. Chem."},{"key":"20346_CR64","doi-asserted-by":"publisher","first-page":"29063","DOI":"10.1038\/srep29063","volume":"6","author":"C Buonsanti","year":"2016","unstructured":"Buonsanti, C. et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci. Rep. 6, 29063. https:\/\/doi.org\/10.1038\/srep29063 (2016).","journal-title":"Sci. Rep."},{"key":"20346_CR65","doi-asserted-by":"publisher","first-page":"108275","DOI":"10.1016\/j.clim.2019.108275","volume":"209","author":"A Gonzalez-Lopez","year":"2019","unstructured":"Gonzalez-Lopez, A. et al. Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clin. Immunol. 209, 108275. https:\/\/doi.org\/10.1016\/j.clim.2019.108275 (2019).","journal-title":"Clin. Immunol."},{"key":"20346_CR66","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1002\/anie.202015362","volume":"60","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7\/8 agonist-adjuvanted recombinant spike protein vaccine. Angew Chem. Int. Ed. Engl. 60, 9467\u20139473. https:\/\/doi.org\/10.1002\/anie.202015362 (2021).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"20346_CR67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tim.2013.11.007","volume":"22","author":"KH Mills","year":"2014","unstructured":"Mills, K. H., Ross, P. J., Allen, A. C. & Wilk, M. M. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol. 22, 49\u201352. https:\/\/doi.org\/10.1016\/j.tim.2013.11.007 (2014).","journal-title":"Trends Microbiol."},{"key":"20346_CR68","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.coi.2019.03.006","volume":"59","author":"P Kapil","year":"2019","unstructured":"Kapil, P. & Merkel, T. J. Pertussis vaccines and protective immunity. Curr. Opin. Immunol. 59, 72\u201378. https:\/\/doi.org\/10.1016\/j.coi.2019.03.006 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"20346_CR69","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl. Acad. Sci. USA 111, 787\u2013792. https:\/\/doi.org\/10.1073\/pnas.1314688110 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20346_CR70","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0168-3659(00)00221-2","volume":"67","author":"AJ Kuijpers","year":"2000","unstructured":"Kuijpers, A. J. et al. In vivo and in vitro release of lysozyme from cross-linked gelatin hydrogels: A model system for the delivery of antibacterial proteins from prosthetic heart valves. J. Control Release 67, 323\u2013336. https:\/\/doi.org\/10.1016\/s0168-3659(00)00221-2 (2000).","journal-title":"J. Control Release"},{"key":"20346_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2017.09.034","volume":"266","author":"L Northrup","year":"2017","unstructured":"Northrup, L. et al. Co-delivery of autoantigen and dexamethasone in incomplete Freund\u2019s adjuvant ameliorates experimental autoimmune encephalomyelitis. J. Control Release 266, 156\u2013165. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.034 (2017).","journal-title":"J. Control Release"},{"key":"20346_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y. et al. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12, 263\u2013271. https:\/\/doi.org\/10.1208\/s12248-010-9185-1 (2010).","journal-title":"AAPS J."},{"key":"20346_CR73","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/mi.2017.110","volume":"11","author":"RHM Raeven","year":"2018","unstructured":"Raeven, R. H. M. et al. Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. Mucosal. Immunol. 11, 1009. https:\/\/doi.org\/10.1038\/mi.2017.110 (2018).","journal-title":"Mucosal. Immunol."},{"key":"20346_CR74","doi-asserted-by":"publisher","first-page":"e0134640","DOI":"10.1371\/journal.pone.0134640","volume":"10","author":"L Ganapathi","year":"2015","unstructured":"Ganapathi, L. et al. The imidazoquinoline toll-like receptor-7\/8 agonist hybrid-2 potently induces cytokine production by human newborn and adult leukocytes. PLoS ONE 10, e0134640. https:\/\/doi.org\/10.1371\/journal.pone.0134640 (2015).","journal-title":"PLoS ONE"},{"key":"20346_CR75","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","volume":"34","author":"AJ Smith","year":"2016","unstructured":"Smith, A. J. et al. Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants. Vaccine 34, 4304\u20134312. https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.080 (2016).","journal-title":"Vaccine"},{"key":"20346_CR76","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.bmcl.2015.01.037","volume":"25","author":"HG Bazin","year":"2015","unstructured":"Bazin, H. G. et al. Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives. Bioorganic Med. Chem. Lett. 25, 1318\u20131323. https:\/\/doi.org\/10.1016\/j.bmcl.2015.01.037 (2015).","journal-title":"Bioorganic Med. Chem. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20346-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T06:08:07Z","timestamp":1666073287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20346"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20346-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1713108\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.D., F.B., B.B., D.S., E.N., H.G.B., D.B., O.L. and J.T.E. are named inventors on several patent applications related to vaccine adjuvants. J.T.E., D.B. and H.G.B. are employees and co-founders of Inimmune Corporation. F.B. has signed consulting\u00a0agreements\u00a0with Merck Sharp & Dohme Corp.\u00a0(a subsidiary of Merck & Co., Inc.), Sana Biotechnology, Inc., and F. Hoffmann-La Roche Ltd.\u00a0These\u00a0commercial relationships\u00a0are\u00a0unrelated to the current study. Rest of the authors do not have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16860"}}